中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Ginsenoside-Rd for Acute Ischemic Stroke

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Xijing Hospital

关键词

抽象

The purpose of this study is to evaluate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

描述

A major contributor to brain injury after stroke is disordered inward flow of Ca2+ and its toxic accumulation in the nervous system following cerebral ischemia. Ginsenoside-Rd, a purified component from total saponins of Panax notoginseng, has a molecular formula of C48H82O18•3H2O with a molecular weight of 1001.2. Ginsenoside-Rd has been shown to inhibit receptor-operated Ca2+ influx through receptor-and-store-operated Ca2+ channels (ROCC) , attenuate oxidative stress in stroke, reduce the size of the cerebral infarction and preserve brain functioning in animal models of acute ischemic stroke.

日期

最后验证: 11/30/2007
首次提交: 12/26/2007
提交的预估入学人数: 01/09/2008
首次发布: 01/10/2008
上次提交的更新: 08/29/2010
最近更新发布: 08/31/2010
实际学习开始日期: 08/31/2005
预计主要完成日期: 05/31/2006
预计完成日期: 08/31/2006

状况或疾病

Ischemic Stroke

干预/治疗

Drug: ginsenoside-Rd 10mg

Drug: placebo

Drug: ginsenoside-Rd 20mg

相 2

手臂组

干预/治疗
Experimental: ginsenoside-Rd 10mg
both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
Drug: ginsenoside-Rd 10mg
infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
Placebo Comparator: placebo
2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
Drug: placebo
infusion placebo (group B)once a day and continued for 14 days
Experimental: ginsenoside-Rd 20mg
2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
Drug: ginsenoside-Rd 20mg
infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- between 18 to 75 years

- the first episode

- from onset to admission within 72 hours

- NIHSS scores:5~22

Exclusion Criteria:

- had other intracranial pathologies (e.g., tumor, infection)

- had a neurologic or psychiatric disease

- had a coexisting condition that limited their life expectancy

- had significant drug or alcohol misuse

- had high-grade carotid artery stenosis for which surgery was planned

- were pregnant or nursing

- participated in a clinical trial with an investigational drug or device within the past 3 months

- were unlikely to be available for follow-up

结果

主要结果指标

1. NIHSS scores [15±1 days]

次要成果指标

1. NIHSS scores [8 days]

2. the Barthel index [8 days]

3. the Barthel index [15 days]

4. the modified Rankin scale [15 days]

5. the modified Rankin scale [90 days]

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge